Answer
May 13, 2026 - 08:36 AM
Survodutide, developed by Boehringer Ingelheim and Zealand Pharma for obesity and NASH, is currently in phase 3 clinical trials as of 2024. If trials are successful, experts anticipate that regulatory approval and market launch could occur as early as 2026. However, the exact launch date will depend on trial outcomes and regulatory review timelines.
